

**From:** [Susan Leveille](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Subject:** RE: Jazz Pharmaceuticals, Inc. New Drug Reporting - 30 day Notice  
**Date:** Wednesday, December 2, 2020 3:27:45 PM

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Following up to the 3 day notice sent on November 4, 2020, please find the 30 day notice for the Jazz Pharmaceuticals, Inc. product Xywav below:

(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally – **Not publically available**

(2) the estimated volume of patients who may be prescribed the drug – **not publicly available**

(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval – **Breakthrough Therapy = no, Priority Review = yes**

(4) the date and price of acquisition if the drug was not developed by the manufacturer – **N/A**

Let me know if additional information is needed at this time.

Sincerely,

Susan Leveille  
Sr. Director, Contract Operations, Government Pricing & Analytics

---

**From:** Susan Leveille  
**Sent:** Wednesday, November 4, 2020 4:47 AM  
**To:** [AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)  
**Subject:** Jazz Pharmaceuticals, Inc. New Drug Reporting - 3 day Notice

**Pursuant to § 4637. Notice Of Introduction Of New High-Cost Prescription Drugs**

A prescription drug manufacturer shall notify the Office of the Attorney General in writing if it is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. Please see below:

**Name of the drug manufacturer:** Jazz Pharmaceuticals, Inc.

**Name of the prescription drug:** Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution

**Anticipated date of release:** November 2, 2020

Let me know if additional information is needed at this time.

Sincerely,

Susan Leveille

Sr. Director, Contract Operations, Government Pricing & Analytics

**\*\* ATTENTION: CONFIDENTIAL \*\***

This email message is for the sole use of the intended recipient(s) and may contain confidential and/or privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact me by reply email and destroy all copies of the original message. Thank you.